Latest From Pfenex Inc.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Pfenex believes it and commercial partner Alvogen could enjoy an extended period as the only direct competitor to Eli Lilly’s Forteo teriparatide reference brand in the US.
Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Generic Drugs
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfenex Inc.
- Senior Management
Evert (Eef) Schimmelpennink, Pres. & CEO
Susan Knudson, CFO
Patrick K Lucy, CBO
Hubert C Chen, MD, CMO & CSO
- Contact Info
Phone: (858) 352-4400
10790 Roselle St.
San Diego, CA 92121
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.